Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 18Recurrence 2Smoldering Multiple Myeloma 1Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Ganglioneuroblastoma 1

Interventions

Magnetic Resonance Spectroscopy 5Cyclophosphamide 5dinutuximab 3Topotecan 3Etoposide 3Doxorubicin 3Carboplatin 3Biopsy 3sargramostim 2Vincristine 2Thiotepa 2Stem Cell Transplantation 2Specimen Handling 2Radiation 2Platinum 2Melphalan 2Isotretinoin 2Colony-Stimulating Factors 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2iberdomide 1gallium Ga 68 dotatate 1fludarabine 1Watchful Waiting 1Transurethral Resection of Bladder 1Temozolomide 1Razoxane 1Radiotherapy 1Proton Therapy 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ganglioneuroblastoma × iberdomide × 90 days × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡